+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


An Introduction to Statistics in Early Phase Trials

  • ID: 2170537
  • Book
  • 264 Pages
  • John Wiley and Sons Ltd
1 of 3
All new medicines and devices undergo early phase trials to assess, interpret and better understand their efficacy, tolerability and safety.An Introduction to Statistics in Early Phase Trials describes the practical design and analysis of these important early phase clinical trials and provides the crucial statistical basis for their interpretation. It clearly and concisely provides an overview of the most common types of trials undertaken in early phase clinical research and explains the different methodologies used. The impact of statistical technologies on clinical development and the statistical and methodological basis for making clinical and investment decisions are also explained.
  • Conveys key ideas in a concise manner understandable by non–statisticians
  • Explains how to optimise designs in a constrained or fixed resource setting
  • Discusses decision making criteria at the end of Phase II trials
  • Highlights practical day–to–day issues and reporting of early phase trials

An Introduction to Statistics in Early Phase Trials is an essential guide for all researchers working in early phase clinical trial development, from clinical pharmacologists and pharmacokineticists through to clinical investigators and medical statisticians. It is also a valuable reference for teachers and students of pharmaceutical medicine learning about the design and analysis of clinical trials.

Note: Product cover images may vary from those shown
2 of 3
Chapter 1 Early phase trials

Chapter 2 Introduction to pharmacokinetics

Chapter 3 Sample size calculations for clinical trials

Chapter 4 Crossover trial basics

Chapter 5 Multi–period crossover trials

Chapter 6 First time into man

Chapter 7 Bayesian and frequentist methods

Chapter 8 First–time–into–new–population studies

Chapter 9 Bioequivalence studies

Chapter 10 Other Phase I trials

Chapter 11 Phase II trials: general issues

Chapter 12 Dose response studies

Chapter 13 Phase II trials with toxic therapies

Chapter 14 Interpreting and applying early phase trial results

Chapter 15 Go/No–Go criteria




Note: Product cover images may vary from those shown
3 of 3


4 of 3
Steven Julious
Say–Beng Tan
David Machin
Note: Product cover images may vary from those shown